Americas

“The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston – and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:
CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery
Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.”

Connect with top-notch industry speakers delivering impactful presentations with practical solutions and best practices to take you to the next level in leading and managing the business aspects of clinical trials. It’s a place where clinical research professionals can connect on the latest topics, trends and technologies for streamlining the business aspects of clinical trials. Areas covered are clinical trial outsourcing and vendor management, contracting and budgeting, financial management, business operations and accelerating clinical study start-up.

Capture the unmatched potential of these versatile stem cells in regenerative medicine and cell therapy by advancing scale-up, differentiation and quality to reduce variability and ensure stable and robust cell lines. Gain valuable insights from industry experts, through exclusive talks and discussions, into approaches to transform your manufacturing processes by exploring technology innovations, leveraging automation and AI, evolving analytics and advancing cryopreservation.

The Innate Killer Summit returns for its 7th year as the industry-defining forum advancing the field to achieve clinical success. Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies. Promising unpublished data, interactive discussion, and engaging networking opportunities join the 7th Innate Killer Summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

Join us in person for this annual event which brings together institutional investors from across the globe with some of the best and most promising growth companies in our core sectors – Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail.

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,700 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on one meetings while highlighting the significant clinical and commercial progress in the field.

Gene Therapy for Rare Disorders is dedicated to overcoming the unique drug development challenges encountered in transforming gene therapy concepts into reality for rare disease patients in need.As the gene therapy field strives to strike the balance between clinical efficacy and product safety in the context of mounting regulatory scrutiny, Gene Therapy for Rare Disorders provides in-depth insights from experts who know how to drive clinical progress, optimize manufacturing, and demonstrate the value of gene therapy products to regulators, payers, and patients.Across four days, this meeting will unite 500+ leading experts in Boston from innovative biotechs, large pharma, academia, and key service provider companies, delivering actionable insights and valuable networking opportunities to accelerate gene therapy progress.

The purpose of the CDISC Interchanges is to bring together those interested in improving medical research and accelerating the development of therapies for patients worldwide. At this event, we will discuss the successes, challenges, and opportunities for collaboration among stakeholders developing and implementing clinical research data standards and, through other means, streamlining the biomedical research process

Advance your innovative biologics pipeline and elevate your engineering, targets and machine learning strategies – accelerating your path to the clinic and beyond.